Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 4 | 13 | +0,11 % | ||
| REVOLUTION MEDICINES | 3 | 5 | +1,62 % | ||
| COMPASS PATHWAYS | 2 | 11 | 0,00 % | ||
| AMGEN | 1 | 27 | +0,03 % | ||
| MODERNA | 1 | 16 | +0,12 % | ||
| TRAVERE THERAPEUTICS | 1 | 11 | -1,15 % | ||
| ZAI LAB LTD ADR | 1 | 6 | 0,00 % | ||
| GRIFOLS | 1 | 4 | -0,70 % | ||
| ANAVEX LIFE SCIENCES | 1 | - | +2,30 % | ||
| AMNEAL PHARMACEUTICALS | 1 | - | -1,69 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21:06 | Amneal rated Buy in new research coverage at UBS as growth pipeline expands | 4 | Seeking Alpha | ||
| 20:26 | Mesoblast Limited (MESO), One of the Best Long-Term ASX Stocks To Buy Right Now; See Why | 2 | Insider Monkey | ||
| 20:22 | Revolution Medicines: Starke Phase-1-Daten für Lungenkrebsmedikament treiben Aktie an | 3 | Investing.com Deutsch | ||
| 20:06 | Revolution Medicines, Inc.: Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 20:06 | Revolution Medicines reports phase 1 data for lung cancer drug | 3 | Investing.com | ||
| 19:26 | Zai Lab (ZLAB), Amgen (AMGN) Partner to Evaluate Combination Lung Cancer Therapy | 6 | Insider Monkey | ||
| 19:26 | Grifols (GRFS) Unveils AI-Driven Data for Early Parkinson's Disease Detection | 1 | Insider Monkey | ||
| 19:26 | Here is Why Travere (TVTX) is an Overlooked Growth Stocks to Buy Now | 1 | Insider Monkey | ||
| 19:26 | FDA Accepts Ultragenyx (RARE) BLA for Sanfilippo Syndrome Gene Therapy UX111 | 1 | Insider Monkey | ||
| 19:26 | Arcutis Biotherapeutics (ARQT) Presents Positive Phase 2 Data for ZORYVE Cream in Infants | 1 | Insider Monkey | ||
| 10:50 | ANAVEX LIFE SCIENCES CORP: Struktur in der Stille | 3 | Maximilian Berger | ||
| 10:06 | Compass Pathways Cheers Trump Order To Accelerate Access To Psychedlic Drug Treatements: 'Recognizes Profound Urgency Of Mental Health Crisis' | 1 | Benzinga.com | ||
| 09:30 | ANALYSE: Curevac - Was hinter den Kulissen passiert - So reagieren erfahrene Anleger jetzt | Hebelschein-Spekulant | |||
| 09:12 | Durchbruch in der Psychotherapie: Emyria meldet 50% Remission - Ein neuer "BioNTech-Moment" für die Mental-Health-Branche? | Small- & Micro Cap Investment | |||
| 06:30 | Sanofi's Nuvaxovid Shows Superior Tolerability Over Moderna's MNEXSPIKE In COMPARE Study | 554 | AFX News | PARIS (dpa-AFX) - Sanofi's (SNY, SNYNF,SAN.PA) protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2705), demonstrated a significantly better tolerability profile compared to Moderna's latest... ► Artikel lesen | |
| Sa | Compass Pathfinder Limited: Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments | 755 | Business Wire | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical... ► Artikel lesen | |
| Sa | Notable analyst calls this week: Tesla, Qualcomm and Biogen among top picks | 23 | Seeking Alpha | ||
| Sa | Sanofi: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study | 715 | GlobeNewswire (Europe) | ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study powered to directly compare the... ► Artikel lesen | |
| Sa | BioNTech Aktie: Kurs dreht auf! Zulassungsantrag, Pipeline-Power und ein Einstiegssignal! | 2.417 | FinanzNachrichten.de | © Foto: Pexels (Symbolbild)Lange war BioNTech für viele Anleger ein Sorgenkind. Der Rückgang des Corona-Geschäfts drückte auf den Kurs, der Abgang der Gründer sorgte für Unsicherheit. Dann kam der Absturz... ► Artikel lesen | |
| Sa | argenx SE: argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP | 3 | GlobeNewswire (USA) |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.